Last updated: February 4, 2026
What is Gadobenate Dimeglumine?
Gadobenate dimeglumine (brand name Multihance) is a gadolinium-based contrast agent (GBCA) approved for magnetic resonance imaging (MRI). It enhances image quality by increasing contrast between normal and abnormal tissues. Approved by the FDA in 2004, it is chiefly used for CNS, liver, and breast imaging.
What is the Market Profile for Gadobenate Dimeglumine?
The global MRI contrast agent market exceeded USD 2 billion in 2022, with a compound annual growth rate (CAGR) of approximately 5% from 2023 to 2030.[1] Gadobenate dimeglumine currently captures a modest share of this market, estimated at below 5%, due to limited indications and competing agents. Major competitors include gadopentetate dimeglumine (Magnevist) and gadobutrol (Gadavist).
What Are the Core Drivers and Challenges?
Drivers
- Increasing MRI Procedures: The number of MRI scans globally exceeds 50 million annually, driven by rising prevalence of cancer, neurology, and cardiovascular diseases.
- Advances in Contrast Media Technology: Development of high-relaxivity agents like gadobenate dimeglumine promotes improved image quality with lower doses.
- Regulatory Incentives: Pending FDA approvals for expanded indications could expand use cases.
Challenges
- Regulatory and Safety Concerns: Gadolinium retention and NSF (nephrogenic systemic fibrosis) cases lead regulators to limit certain agents.
- Competition with Lower-Price Agents: Less expensive, generic GBCAs erode market share of branded agents.
- Limited Differentiation: Similar efficacy among GBCAs reduces incentive to switch or adopt new agents.
What Are the Key Financial and Patent Aspects?
Patent and Exclusivity Timeline
Gadobenate dimeglumine’s original patent expired in 2014, with many markets allowing generics entry. Patent extensions or formulation patents could extend exclusivity in specific regions or formulations until 2024-2026.
Revenue and Pricing
- Pricing: Estimated at USD 20-40 per dose, varying by region and indication.
- Sales: Limited to niche MRI applications. Shengli Medical Imaging's reports cite annual sales in the USD 50-100 million range for gadobenate dimeglumine globally.
- Market Share: Less than 5% of total GBCA market, with US share around 2-3%.
R&D and Manufacturing Costs
Manufacturing relies on complex procedures for stable gadolinium chelates. Development costs prior to approval approximate USD 100-200 million, including clinical trials.
What Are the Investment Considerations?
Strengths
- Specialized MRI contrast agent with unique relaxivity profile.
- Potential for incremental sales through indication expansions.
- Stable manufacturing process with existing regulatory approvals.
Weaknesses
- Patent expiration risks reinforce entry of generic competitors post-2024.
- Market share is limited due to safety concerns and pricing pressures.
- Growing regulatory scrutiny diminishes future sales prospects.
Opportunities
- Expand indications to neurology or oncology.
- Secure regulatory approval in emerging markets.
- Develop next-generation agents with improved safety profiles.
Threats
- Generic product proliferation post-patent expiry.
- Shift to alternative imaging techniques without contrast agents.
- Regulatory restrictions on GBCAs due to safety concerns.
What Is the Outlook for Investors and R&D?
Gadobenate dimeglumine is positioned as a niche agent within the broader GBCA market. The absence of strong patent protection beyond 2024 limits long-term revenue potential unless new indications or formulations are approved. R&D investments are primarily strategic for pipeline agents rather than the existing molecule. Market share growth hinges on regulatory expansion and demonstrated safety advantages.
Key Takeaways
- Gadobenate dimeglumine is a specialized MRI contrast agent with moderate revenue and limited patent life remaining.
- Competitive pressures and safety concerns are major market constraints.
- Incremental growth possible via indication expansion and emerging markets.
- Post-2024, generic competition will likely erode profitability unless new formulations or uses are developed.
- Investors should weigh the molecule’s niche positioning against patent expiry risks and evolving safety regulations.
FAQs
1. When does gadobenate dimeglumine's patent protection expire?
Patent protection in various regions expires between 2024 and 2026, opening markets for generics.
2. Are there significant safety concerns associated with gadobenate dimeglumine?
Yes, similar to other GBCAs, concerns about gadolinium retention and NSF have been raised, prompting regulatory review.
3. What markets offer growth opportunities for gadobenate dimeglumine?
Emerging markets with increasing MRI utilization and potential for indication expansion represent growth avenues.
4. What is the typical price per dose of gadobenate dimeglumine?
Prices generally range from USD 20 to 40 per dose, with variability based on region and healthcare system.
5. How does gadobenate dimeglumine compare to other GBCAs?
It has higher relaxivity than some agents, offering better contrast at lower doses but faces stiff competition from generic and alternative agents with similar efficacy.
[1] MarketsandMarkets. "Contrast Agents Market by Product, Application, and Region — Global Forecast to 2030," 2023.
